Chronic Hepatitis C
More evidence hails RNA interference as a means for treating hepatitis C virus
Published in Hepatitis Weekly, April 21st, 2003
"RNA interference represents an exciting new technology that could have therapeutic applications for the treatment of viral infections. Hepatitis C virus (HCV) is a major cause of chronic liver disease and affects >270 million individuals worldwide. The HCV genome is a single-stranded RNA that functions as both a messenger RNA and replication template, making it an attractive target for the study of RNA interference," scientists in Canada report.
"Double-stranded small interfering RNA (siRNA) molecules designed to target the HCV genome were introduced through...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-04-21)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Doctors urge certain hepatitis C virus nonresponders to undergo more therapy - Minority Health
Increased iron stores are a challenge to African-Americans with hepatitis C - Cirrhosis
A new scoring system predicts the risk for liver cancer in hepatitis patients - Inflammatory Disease
Researchers attribute transverse myelitis to chronic hepatitis C - Neuroscience
Cerebral dysfunction is a complication of chronic hepatitis C - Epidemiology
Several factors cause divergent hepatitis C virus genotypes in renal patients - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
